The LOTEMAX (loteprednol etabonate ophthalmic gel) gel is described as a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
Loteprednol etabonate, the active ingredient in LOTEMAX gel, was first approved as an ocular anti-inflammatory agent by FDA in 1998.
Related Articles on Ophthalmology:
Ophthalmologist on the Move: Dr. Steven Brady Joins WA’s Cascade Eye & Skin Centers
Ophthalmologist Dr. Robert Massof Receives ‘Champion of Change’ Honor at White House
Global Ophthalmology Devices Market Projected to Reach $18B in 2018
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
